New Study Shows Olaparib Benefits Those Newly Diagnosed

Olaparib (Lynparza), a PARP inhibitor is currently being used in the treatment of recurrent ovarian cancer. This study, recently published in the New England Journal of Medicine, showed that over 66% of women given olaparib in conjunction with standard chemo during the initial treatment of advanced OC had not relapsed after 3 years. The relapse rate is otherwise closer to 70% after 3 years.

The study involved 391 patients who had advanced (Stage 3 or 4) serous, primary peritoneal, endometrioid or fallopian tube OC who had a BRCA 1, 2 or both mutation. These women had either a partial or full response from initial chemo.

The study is being hailed as a "breakthrough" in the treatment of ovarian cancer. To read more about this study, follow this link.